SONY CORPORATE SESSION Strategies for managing factors affecting cell therapy efficacy
Wednesday, May 31, 2023 12:00 PM - 01:00 PM
252B
Corporate Session
Strategies for managing factors affecting cell therapy efficacy
Chair
Patrick Hanley, PhD, Chief and Director, Cellular Therapy Program Associate Professor of Pediatrics , Children's National Hopital, USA
Speakers
Aude G. Chapuis, Physician and Associate Professor, Fred Hutch, USA
Cheryl Cox, Core Operations Director, Moffitt Cancer Center, USA
Maxime Danilo, Team leader- Late Process Development & Analytics, Center of Experimental Therapeutics (CTE) of the CHUV, Switzerland
Steven Highfill, Director of Product Development, Center for Cellular Engineering at National Institutes of Health (NIH), USA
Adoptive cell therapies such as CAR-T and those in the form of tumor-infiltrating lymphocytes (TILs), which harness the body’s own natural defenses, have brought unprecedented advances in the field of cancer immunotherapy. The successes of CAR-T cell therapy has led to U.S. Food and Drug Administration approvals for the treatment of multiple cancer types.
These cellular therapies offer the promise of minimal toxicities with the benefit of long-term immune protection. CAR-T and antitumor treatments using TILs have shown promising results. Multiple clinical trials are being conducted worldwide to further optimize this treatment modality.
In this expert roundtable session, we will explore specific T-cell attributes that influence the performance of adoptive T-cell transfers, such as early memory T-cell populations in CAR-T and in vivo antitumor treatments using TILs.
We will also focus on different parameters affecting CAR-T efficacy and talk about the advantages and disadvantages of different technologies for controlling T-cell phenotypes.
- Advantages of leveraging T cell subtypes and discussion of methods available
- Importance of reproducibility and automation in the overall Cell therapy manufacturing workflow
Chair
Patrick Hanley, PhD, Chief and Director, Cellular Therapy Program Associate Professor of Pediatrics , Children's National Hopital, USA
Speakers
Aude G. Chapuis, Physician and Associate Professor, Fred Hutch, USA
Cheryl Cox, Core Operations Director, Moffitt Cancer Center, USA
Maxime Danilo, Team leader- Late Process Development & Analytics, Center of Experimental Therapeutics (CTE) of the CHUV, Switzerland
Steven Highfill, Director of Product Development, Center for Cellular Engineering at National Institutes of Health (NIH), USA
Adoptive cell therapies such as CAR-T and those in the form of tumor-infiltrating lymphocytes (TILs), which harness the body’s own natural defenses, have brought unprecedented advances in the field of cancer immunotherapy. The successes of CAR-T cell therapy has led to U.S. Food and Drug Administration approvals for the treatment of multiple cancer types.
These cellular therapies offer the promise of minimal toxicities with the benefit of long-term immune protection. CAR-T and antitumor treatments using TILs have shown promising results. Multiple clinical trials are being conducted worldwide to further optimize this treatment modality.
In this expert roundtable session, we will explore specific T-cell attributes that influence the performance of adoptive T-cell transfers, such as early memory T-cell populations in CAR-T and in vivo antitumor treatments using TILs.
We will also focus on different parameters affecting CAR-T efficacy and talk about the advantages and disadvantages of different technologies for controlling T-cell phenotypes.
Sponsored by:
Patrick Hanley PhD
Chief and Director, Cellular Therapy Program Associate Professor of Pediatrics
Children's National Hopital
Chair
Chief and Director, Cellular Therapy Program Associate Professor of Pediatrics
Children's National Hopital
Chair
Cheryl Cox MT(ASCP), CSSMBB, CABP(H)
Director Operations Cell Therapy
Moffitt Cancer Center and Research Institute
Speaker
Director Operations Cell Therapy
Moffitt Cancer Center and Research Institute
Speaker
Maxime Danilo
Head of Late Process development & Analytics
Center of Experimental Therapeutics (CTE) of the CHUV in Lausanne, Switzerland
Speaker
Head of Late Process development & Analytics
Center of Experimental Therapeutics (CTE) of the CHUV in Lausanne, Switzerland
Speaker